27. Peri- und Postmenopause – Diagnostik und Therapie

Zurück zum Zitat Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner RL, Brzyski RG, Caan BJ (2004) Effects of conjugated equine estrogen in postmenopausal women with a hysterectomy. JAMA 291:1701–1712CrossRef Anderson GL, Limacher M, Assaf AR, Bassford T, Beresford SA, Black H, Bonds D, Brunner RL, Brzyski RG, Caan BJ (2004) Effects of conjugated equine estrogen in postmenopausal women with a hysterectomy. JAMA 291:1701–1712CrossRef

Zurück zum Zitat Avis NE, Crawford SL, Greendale G, Bromberger JT, Everson-Rose SA, Gold EB, Hess R, Joffe H, Kravitz HM, Tepper PG, Thurston RC (2015) Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med 175(4):531–539 Avis NE, Crawford SL, Greendale G, Bromberger JT, Everson-Rose SA, Gold EB, Hess R, Joffe H, Kravitz HM, Tepper PG, Thurston RC (2015) Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med 175(4):531–539

Zurück zum Zitat Avis NE, Colvin A, Bromberger JT, Hess R, Matthews KA, Ory M, Schocken M (2009) Change in health-related quality of life over the menopausal transisiton in an multiethnic cohort of middle-aged women: Study of Womens’s Health Across the Nation (SWAN). Neurology 72(21):1850–1857CrossRef Avis NE, Colvin A, Bromberger JT, Hess R, Matthews KA, Ory M, Schocken M (2009) Change in health-related quality of life over the menopausal transisiton in an multiethnic cohort of middle-aged women: Study of Womens’s Health Across the Nation (SWAN). Neurology 72(21):1850–1857CrossRef

Zurück zum Zitat Beral V, Million Women, Study Collaborators (2003) Breast cancer and hormone-replacement therapy in the million women study. Lancet 362:419–427 (Erratum appears in Lancet 2003 Oct 4; 362(9390):1160)CrossRef Beral V, Million Women, Study Collaborators (2003) Breast cancer and hormone-replacement therapy in the million women study. Lancet 362:419–427 (Erratum appears in Lancet 2003 Oct 4; 362(9390):1160)CrossRef

Zurück zum Zitat Beral V, Bull D, Reeves G, Million Women Study Collaborators (2005) Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 365(9470):1543–1551CrossRef Beral V, Bull D, Reeves G, Million Women Study Collaborators (2005) Endometrial cancer and hormone-replacement therapy in the Million Women Study. Lancet 365(9470):1543–1551CrossRef

Zurück zum Zitat Boardman HM, Hartley L, Eisinga A, Main C, Roqué i Figuls M, Bonfill Cosp X, Gabriel-Sanchez R, Knight B (2015) Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev Mar 10. https://doi.org/10.1002/14651858.cd002229.pub4 Boardman HM, Hartley L, Eisinga A, Main C, Roqué i Figuls M, Bonfill Cosp X, Gabriel-Sanchez R, Knight B (2015) Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev Mar 10. https://​doi.​org/​10.​1002/​14651858.​cd002229.​pub4

Zurück zum Zitat Collaborative Group on Epidemiological Studies of Ovarian Cancer (2015) Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet 385:1835–1842CrossRef Collaborative Group on Epidemiological Studies of Ovarian Cancer (2015) Menopausal hormone use and ovarian cancer risk: individual participant meta-analysis of 52 epidemiological studies. Lancet 385:1835–1842CrossRef

Zurück zum Zitat Gordon JL, Rubinow DR, Eisenlohr-Moul TA, Xia K, Schmidt PJ, Girdler SS (2018) Efficacy of transdermal estradiol and micronized progesterone in the prevention of depressive symptoms in the menopause transition: A randomized clinical trial. JAMA Psychiatry 75(2):149–157CrossRef Gordon JL, Rubinow DR, Eisenlohr-Moul TA, Xia K, Schmidt PJ, Girdler SS (2018) Efficacy of transdermal estradiol and micronized progesterone in the prevention of depressive symptoms in the menopause transition: A randomized clinical trial. JAMA Psychiatry 75(2):149–157CrossRef

Zurück zum Zitat Harlow SD, Goss M, Hall JE et al. (2012) Executive summary of the Stages of Reproductive Aging Workshop + 10: Addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab 97:1159–1168 Harlow SD, Goss M, Hall JE et al. (2012) Executive summary of the Stages of Reproductive Aging Workshop + 10: Addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab 97:1159–1168

Zurück zum Zitat Lattrich C, Hadji P, Ortmann O (2014) Perimenopause Postmenopause und Senium. In: Leidenberger FA, Strowitzki T, Ortmann O (Hrsg) Klinische Endokrinologie für Frauenärzte, 2. Aufl. Springer, Heidelberg Lattrich C, Hadji P, Ortmann O (2014) Perimenopause Postmenopause und Senium. In: Leidenberger FA, Strowitzki T, Ortmann O (Hrsg) Klinische Endokrinologie für Frauenärzte, 2. Aufl. Springer, Heidelberg

Zurück zum Zitat Lin KJ, Cheung WY, Lai JY et al (2012) The effect of estrogen vs. combined estrogen-progestin therapy on the risk of colorectal cancer. Int J Cancer 130:419–430CrossRef Lin KJ, Cheung WY, Lai JY et al (2012) The effect of estrogen vs. combined estrogen-progestin therapy on the risk of colorectal cancer. Int J Cancer 130:419–430CrossRef

Zurück zum Zitat Maki PM, Kornstein SG, Joffe H, Bromberger JT, Freeman EW, Athappilly G, Bobo WV, Rubin LH, Koleva HK, Cohen LS, Soares CN (2018) Board of trustees for The North American Menopause Society (NAMS) and the women and mood disorders task force of the national network of depression centers. Menopause 25(10):1069–1085CrossRef Maki PM, Kornstein SG, Joffe H, Bromberger JT, Freeman EW, Athappilly G, Bobo WV, Rubin LH, Koleva HK, Cohen LS, Soares CN (2018) Board of trustees for The North American Menopause Society (NAMS) and the women and mood disorders task force of the national network of depression centers. Menopause 25(10):1069–1085CrossRef

Zurück zum Zitat Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M, Women’s Health Initiative Investigators (2003) Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349:523–534CrossRef Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, Trevisan M, Black HR, Heckbert SR, Detrano R, Strickland OL, Wong ND, Crouse JR, Stein E, Cushman M, Women’s Health Initiative Investigators (2003) Estrogen plus progestin and the risk of coronary heart disease. N Engl J Med 349:523–534CrossRef

Zurück zum Zitat Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, Anderson G, Howard BV, Thomson CA, LaCroix AZ, Wactawski-Wende J, Jackson RD, Limacher M, Margolis KL, Wassertheil-Smoller S, Beresford SA, Cauley JA, Eaton CB, Gass M, Hsia J, Johnson KC, Kooperberg C, Kuller LH, Lewis CE, Liu S, Martin LW, Ockene JK, O’Sullivan MJ, Powell LH, Simon MS, Van Horn L, Vitolins MZ, Wallace RB (2013) Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the women’s health Initiative randomized trials. JAMA 310:1353–1368CrossRef Manson JE, Chlebowski RT, Stefanick ML, Aragaki AK, Rossouw JE, Prentice RL, Anderson G, Howard BV, Thomson CA, LaCroix AZ, Wactawski-Wende J, Jackson RD, Limacher M, Margolis KL, Wassertheil-Smoller S, Beresford SA, Cauley JA, Eaton CB, Gass M, Hsia J, Johnson KC, Kooperberg C, Kuller LH, Lewis CE, Liu S, Martin LW, Ockene JK, O’Sullivan MJ, Powell LH, Simon MS, Van Horn L, Vitolins MZ, Wallace RB (2013) Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the women’s health Initiative randomized trials. JAMA 310:1353–1368CrossRef

Zurück zum Zitat Manson JE, Aragaki AK, Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Chlebowski RT, Howard BV, Thomson CA, Margolis KL, Lewis CE, Stefanick ML, Jackson RD, Johnson KC, Martin LW, Shumaker SA, Espeland MA, Wactawski-Wende J, WHI Investigators (2017) Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the women’s health initiative randomized trials. JAMA 318(10):927–938CrossRef Manson JE, Aragaki AK, Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Chlebowski RT, Howard BV, Thomson CA, Margolis KL, Lewis CE, Stefanick ML, Jackson RD, Johnson KC, Martin LW, Shumaker SA, Espeland MA, Wactawski-Wende J, WHI Investigators (2017) Menopausal hormone therapy and long-term all-cause and cause-specific mortality: the women’s health initiative randomized trials. JAMA 318(10):927–938CrossRef

Zurück zum Zitat Manson JE, Kaunitz AM (2016) Menopause management-getting clinical care back on track. N Engl J Med 374:803–806CrossRef Manson JE, Kaunitz AM (2016) Menopause management-getting clinical care back on track. N Engl J Med 374:803–806CrossRef

Zurück zum Zitat Menopause Full Guideline, Methods, evidence and recommendations, Version 1.5, 12 November 2015, National Institute for Health and Care Excellence (NICE) Guideline. https://www.nice.org.uk/guidance/ng23/evidence/full-guideline-pdf-559549261. Zugegriffen: 31. Juli 2018 Menopause Full Guideline, Methods, evidence and recommendations, Version 1.5, 12 November 2015, National Institute for Health and Care Excellence (NICE) Guideline. https://​www.​nice.​org.​uk/​guidance/​ng23/​evidence/​full-guideline-pdf-559549261. Zugegriffen: 31. Juli 2018

Zurück zum Zitat Moegele M, Buchholz S, Seitz S, Ortmann O (2012) Vaginal estrogen therapy in postmenopausal breast cancer patients treated with aromatase inhibitors. Arch Gynecol Obstet 285(5):1397–1402. https://doi.org/10.1007/s00404-011-2181-6CrossRefPubMed Moegele M, Buchholz S, Seitz S, Ortmann O (2012) Vaginal estrogen therapy in postmenopausal breast cancer patients treated with aromatase inhibitors. Arch Gynecol Obstet 285(5):1397–1402. https://​doi.​org/​10.​1007/​s00404-011-2181-6CrossRefPubMed

Zurück zum Zitat Mørch LS, Lidegaard Ø, Keiding N, Løkkegaard E, Kjær SK (2016) The influence of hormone therapies on colon and rectal cancer. European Journal Epidemiology 31:481–489. https://doi.org/10.1007/s10654-016-0116-zCrossRef Mørch LS, Lidegaard Ø, Keiding N, Løkkegaard E, Kjær SK (2016) The influence of hormone therapies on colon and rectal cancer. European Journal Epidemiology 31:481–489. https://​doi.​org/​10.​1007/​s10654-016-0116-zCrossRef

Zurück zum Zitat Mueck AO, Ruan X, Prasauskas V, Grob P, Ortmann O (2018) Treatment of vaginal atrophy with estriol and lactobacilli combination: a clinical review. Climacteric 21(2):140–147. https://doi.org/10.1080/13697137.2017.1421923 (Epub 2018 Jan 30)CrossRefPubMed Mueck AO, Ruan X, Prasauskas V, Grob P, Ortmann O (2018) Treatment of vaginal atrophy with estriol and lactobacilli combination: a clinical review. Climacteric 21(2):140–147. https://​doi.​org/​10.​1080/​13697137.​2017.​1421923 (Epub 2018 Jan 30)CrossRefPubMed

Zurück zum Zitat Nelson HD, Haney E, Humphrey L, Miller J, Nedrow A, Nicolaidis C, Vesco K, Walker M, Bougatsos C, Nygren P (2005) Management of Menopause-Related Symptoms. Evid Rep Technol Assess 120:12 Nelson HD, Haney E, Humphrey L, Miller J, Nedrow A, Nicolaidis C, Vesco K, Walker M, Bougatsos C, Nygren P (2005) Management of Menopause-Related Symptoms. Evid Rep Technol Assess 120:12

Zurück zum Zitat North American Menopause Society. POSITION STATEMENT (2013) Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause 20(9):888–902. https://doi.org/10.1097/gme.0b013e3182a122c2CrossRef North American Menopause Society. POSITION STATEMENT (2013) Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society. Menopause 20(9):888–902. https://​doi.​org/​10.​1097/​gme.​0b013e3182a122c2​CrossRef

Zurück zum Zitat North American Menopause Society. POSITION STATEMENT (2017) The 2017 hormone therapy position statement of The North American Menopause Society. Menopause 24(7):728–753. https://doi.org/10.1097/gme.0000000000000921CrossRef North American Menopause Society. POSITION STATEMENT (2017) The 2017 hormone therapy position statement of The North American Menopause Society. Menopause 24(7):728–753. https://​doi.​org/​10.​1097/​gme.​0000000000000921​CrossRef

Zurück zum Zitat Peri- and Postmenopause – Diagnostik und Interventionen. Leitlinie der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe (S3, AWMF-Registernummer 015-062, 2019). http://www.awmf.org/leitlinien/detail/ll/015-062.html Peri- and Postmenopause – Diagnostik und Interventionen. Leitlinie der Deutschen Gesellschaft für Gynäkologie und Geburtshilfe (S3, AWMF-Registernummer 015-062, 2019). http://​www.​awmf.​org/​leitlinien/​detail/​ll/​015-062.​html

Zurück zum Zitat Prophylaxe, Diagnostik und Therapie der OSTEOPOROSE bei Männern ab dem 60. Lebensjahr und bei postmenopausalen Frauen, Leitlinie des Dachverbands der Deutschsprachigen Wissenschaftlichen Osteologischen Gesellschaften e. V., 2017 Prophylaxe, Diagnostik und Therapie der OSTEOPOROSE bei Männern ab dem 60. Lebensjahr und bei postmenopausalen Frauen, Leitlinie des Dachverbands der Deutschsprachigen Wissenschaftlichen Osteologischen Gesellschaften e. V., 2017

Zurück zum Zitat S3-Leitlinie/Nationale Versorgungsleitlinie Unipolare Depression, Langfassung 2 Aufl., 2015, Version 5, AWMF-Register-Nr.: nvl-005. https://www.awmf.org/uploads/tx_szleitlinien/nvl-005l_S3_Unipolare_Depression_2017-05.pdf S3-Leitlinie/Nationale Versorgungsleitlinie Unipolare Depression, Langfassung 2 Aufl., 2015, Version 5, AWMF-Register-Nr.: nvl-005. https://​www.​awmf.​org/​uploads/​tx_​szleitlinien/​nvl-005l_​S3_​Unipolare_​Depression_​2017-05.​pdf

Zurück zum Zitat Shim SH, Lee SJ, Kim SN (2014) Effects of hormone replacement therapy on the rate of recurrence in endometrial cancer survivors: a meta-analysis. Eur J Cancer 50(9):1628–1637CrossRef Shim SH, Lee SJ, Kim SN (2014) Effects of hormone replacement therapy on the rate of recurrence in endometrial cancer survivors: a meta-analysis. Eur J Cancer 50(9):1628–1637CrossRef

Zurück zum Zitat Wild RA, Wu C, Curb JD, Martin LW, Phillips L, Stefanick M, Trevisan M, Manson JE (2013) Coronary heart disease events in the Women’s Health Initiative hormone trials: effect modification by metabolic syndrome: a nested case-control study within the Women’s Health Initiative randomized clinical trials. Menopause 20(3):254–260. https://doi.org/10.1097/GME.0b013e31826f80e0CrossRefPubMedPubMedCentral Wild RA, Wu C, Curb JD, Martin LW, Phillips L, Stefanick M, Trevisan M, Manson JE (2013) Coronary heart disease events in the Women’s Health Initiative hormone trials: effect modification by metabolic syndrome: a nested case-control study within the Women’s Health Initiative randomized clinical trials. Menopause 20(3):254–260. https://​doi.​org/​10.​1097/​GME.​0b013e31826f80e0​CrossRefPubMedPubMedCentral